Pharmaleaders TV
You are here:  / Breaking News / Business / IDEAYA Biosciences begins patient dosing in phase 1 combination study of IDE196 and binimetinib to treat MUM

IDEAYA Biosciences begins patient dosing in phase 1 combination study of IDE196 and binimetinib to treat MUM

IDEAYA Biosciences, an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the phase 1 combination study of IDE196 and binimetinib, a MEK inhibitor, in metastatic uveal melanoma (MUM). The clinical combination of IDE196 and binimetinib is being evaluated by IDEAYA with binimetinib being supplied by Pfizer pursuant to a clinical trial collaboration and supply agreement.

In the MUM setting, IDEAYA’s clinical development strategy focuses on rational combinations, including MEK, and supporting studies through collaborations, such as the Pfizer clinical trial collaboration and supply agreement. IDEAYA’s strategic objective is to enhance the clinical activity of IDE196 through potential synergistic combinations. In the non-MUM GNAQ/11 hotspot mutation basket trial, including skin melanoma, IDEAYA will continue to evaluate IDE196 monotherapy and potential combinations, such as with binimetinib.

At the AACR Virtual Annual Meeting II held on June 22-24, 2020, IDEAYA presented an abstract on the preclinical evaluation of IDE196 plus MEK combination, entitled “Analysis of drug combinations with the PKC inhibitor IDE196 support dual MEK and PKC inhibition as a rational combination in metastatic uveal melanoma.”

“Our preclinical studies with IDE196 and MEK presented at AACR support our clinical development strategy to focus on combinations as the most promising approach for the MUM indication,” said Mick O’Quigley, vice president, Head of Development Operations. “In addition, we continue to evaluate IDE196 monotherapy and potentially also combinations in the GNAQ/11 hotspot mutation basket trial, in non-MUM indications such as skin melanoma.”

IDEAYA anticipates interim data from the MEK combination study in late 2021 to early 2022, at which time the company will evaluate a potential registrational path for MUM and a potential partnership.

PHARMALEADERS

Pharmaleaders is India’s first opinion based & research driven bi-monthly magazine & has a decade of relentless reporting in Pharma Journalism in an unbiased, fearless & independent way. Over the last one decade, The Magazine has covered some of the biggest voices in the healthcare Industry. Available both in digital & printed format, Pharmaleaders has emerged out as a leading title in voicing the opinion of the healthcare industry.

Follow us
Contact us

Network 7 Meadia Group

Plot 5, NS Road No. 12, JVPD, Juhu Scheme, Mumbai, Maharashtra 400049. editorial@pharmaleaders.tv